Go to content
UR Home

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Schmitz-Winnenthal, Friedrich H. ; Hohmann, Nicolas ; Schmidt, Thomas ; Podola, Lilli ; Friedrich, Tobias ; Lubenau, Heinz ; Springer, Marco ; Wieckowski, Sébastien ; Breiner, Klaus M. ; Mikus, Gerd ; Büchler, Markus W. ; Keller, Anne-Valerie ; Koc, Ruhan ; Springfeld, Christoph ; Knebel, Phillip ; Bucur, Mariana ; Grenacher, Lars ; Haefeli, Walter E. ; Beckhove, Philipp


VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation trial in advanced pancreatic cancer patients demonstrated safety, ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons